Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: Does it really matter?

Nephrology Dialysis Transplantation

Volumn 19, Issue 12, 2004, Pages 2965-2970

  Grooteman, Muriel P C ^a   Nubé, Menso J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bioincompatibility; Cardiovascular disease; Clinical outcome; Dialyser; ESRD; Flux; Haemodialysis

Indexed keywords

CELLULOSE; CELLULOSE ACETATE; CELLULOSE TRIACETATE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; POLYSULFONE; UREA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

AMYLOIDOSIS; BIOCOMPATIBILITY; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CARPAL TUNNEL SYNDROME; COMPLEMENT ACTIVATION; CORONARY ARTERY ATHEROSCLEROSIS; DIALYSIS MEMBRANE; EDITORIAL; EQUIPMENT DESIGN; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MEMBRANE TRANSPORT; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

BIOCOMPATIBLE MATERIALS; ENDOTHELIUM, VASCULAR; EQUIPMENT DESIGN; HUMANS; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 11244344551     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh502     Document Type: Editorial

References (59)

1. Grooteman MP, Nube MJ. Haemodialysis-related bioincompatibility: fundamental aspects and clinical relevance. Neth J Med 1998; 52: 169-178
2. Jungers P, Massy ZA, Khoa TN et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997; 12: 2597-2602
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
4. Boure T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant 2004; 19: 293-296
5. Craddock PR, Hammerschmidt DE, Moldow CF, Yamada O, Jacob HS. Granulocyte aggregation as a manifestation of membrane interactions with complement: possible role in leukocyte margination, microvascular occlusion, and endothelial damage. Semin Hematol 1979; 16: 140-147
6. Bos JC, Grooteman MP, van Houte AJ et al. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997; 12: 1387-1393
7. Dinarello CA. Cytokines: agents provocateurs in hemodialysis? Kidney Int 1992; 41: 683-694
8. Schmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Platelet activation and factor VIII-related von Willebrand factor during hemodialysis. Am J Med 1987; 83: 411-418
9. Borgdorff P, Fekkes D, Tangelder GJ. Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 2002; 106: 2588-2593
10. Bartels PC, Schoorl M, Schoorl M, Wiering JG, Nube MJ. Activation of coagulation during treatment with haemodialysis. Scand J Clin Lab Invest 2000; 60: 283-290
11. Ishii Y, Yano S, Kanai H et al. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron 1996; 73: 407-412
12. Owen WF, Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329: 1001-1006
13. Babb AL, Ahmad S, Bergstrom J, Scribner BH. The middle molecule hypothesis in perspective. Am J Kidney Dis 1981; 1: 46-50
14. Vanholder R, Glorieux G, De Smet R, Lameire N. New insights in uremic toxins. Kidney Int Suppl 2003; S6-S10
15. Locatelli F, Mastrangelo F, Redaelli B et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50: 1293-1302
16. Gerdemann A, Lemke HD, Nothdurft A et al. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 2000; 54: 276-283
17. Wiesholzer M, Harm F, Hauser AC, Pribasnig A, Balcke P. Inappropriately high plasma leptin levels in obese haemodialysis patients can be reduced by high flux haemodialysis and haemodiafiltration. Clin Sci (Lond) 1998; 94: 431-435
18. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995; 5: 1703-1708
19. Van Tellingen A, Grooteman MP, Bartels PC et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001; 59: 342-347
20. Schindler R, Senf R, Frei U. Influencing the inflammatory response of haemodialysis patients by cytokine elimination using large-pore membranes. Nephrol Dial Transplant 2002; 17: 17-19
21. Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000; 15: 840-845
22. Van Stone JC. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J. 1995; 41: M713-M716
23. Bloembergen WE, Hakim RM, Stannard DC et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999; 33: 1-10
24. Stenvinkel P. Endothelial dysfunction and inflammation - is there a link? Nephrol Dial Transplant 2001; 16: 1968-1971
25. Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases - the atherosclerosis risk in communities (ARIC) study. Circulation 1997; 96: 4219-4225
26. Mrowka C, Heintz B, Sieberth HG. Is dialysis membrane type responsible for increased circulating adhesion molecules during chronic hemodialysis? Clin Nephrol 1999; 52: 312-321
27. Papayianni A, Alexopoulos E, Giamalis P et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002; 17: 435-441
28. Rabb H, Calderon E, Bittle PA, Ramirez G. Alterations in soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in hemodialysis patients. Am J Kidney Dis 1996; 27: 239-243
29. Wauters IM, Grooteman M, Schalkwijk C, Wee P, Nube M. Plasma levels of von Willebrand factor in chronic hemodialyisis patients: influence of individual patients and type of dialyser [abstract]. Nephrol Dial Transplant 2003; 18 [Suppl 4]: 194
30. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-196
31. Pannier B, Guerin AP, Marchais SJ et al. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 2000; 57: 1091-1099
32. Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000; 101: 1002-1006
33. Kosch M, Levers A, Barenbrock M et al. Acute effects of haemodialysis on endothelial function and large artery elasticity. Nephrol Dial Transplant 2001; 16: 1663-1668
34. Cross JM, Donald A, Vallance PJ et al. Dialysis improves endothelial function in humans. Nephrol Dial Transplant 2001; 16: 1823-1829
35. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001; 12: 2458-2464
36. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439
37. Zoccali C, Benedetto FA, Mallamaci F et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774
38. Caramelo C, Alcazar R, Gallar P et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 675-677
39. Churchill DN, Bird DR, Taylor DW et al. Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients. Am J Nephrol 1992; 12: 412-418
40. Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996; 16: 484-488
41. Parker TF, III, Wingard RL, Husni L et al. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996; 49: 551-556
42. Schwalbe S, Holzhauer M, Schaeffer J et al. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis? Kidney Int 1997; 52: 1077-1083
43. van Ypersele S, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39: 1012-1019
44. Vanholder R, Smet RD, Glorieux G, Dhondt A. Survival of hemodialysis patients and uremic toxin removal. Artif Organs 2003; 27: 218-223
45. Nube MJ, Grooteman MP. Impact of contaminated dialysate on long-term haemodialysis-related complications: is it really that important? Nephrol Dial Transplant 2001; 16: 1986-1991
46. Leypoldt JK, Cheung AK, Carroll CE et al. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999; 33: 349-355
47. Port FK, Wolfe RA, Hulbert-Shearon TE et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001; 37: 276-286
48. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000; 15 [Suppl 1]: 36-42
49. Bonomini V, Coli L, Scolari MP, Stefoni S. Structure of dialysis membranes and long-term clinical outcome. Am J Nephrol 1995; 15: 455-462
50. Hakim RM, Held PJ, Stannard DC et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50: 566-570
51. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227-1237
52. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096-1101
53. Wright LF. Survival in patients with end-stage renal disease. Am J Kidney Dis 1991; 17: 25-28
54. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
55. Unruh M, Benz R, Greene T et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO study. Kidney Int 2004; 66: 355-366
56. Rocco MV, Paranandi L, Burrowes JD et al. Nutritional status in the HEMO Study cohort at baseline. Hemodialysis. Am J Kidney Dis 2002; 39: 245-256
57. Allon M, Depner TA, Radeva M et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO study. J Am Soc Nephrol 2003; 14: 1863-1870
58. Charra B, Chazot C, Jean G, Laurent G. Long, slow dialysis. Miner Electrolyte Metab 1999; 25: 391-396
59. Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998; 13: 2853-2860